In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Mammography 510(k) Status Recommended By FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Full-field digital mammography systems should be downclassified to Class II, supported by revised guidance as a special control, FDA's Radiological Devices Advisory Panel recommended May 23

You may also be interested in...



Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule

Two-dimensional digital mammography systems, such as those made by Hologic and GE Healthcare, can now enter the market through the 510(k) versus PMA route, according to a final rule and special controls guidance issued Nov. 4.

Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule

Two-dimensional digital mammography systems, such as those made by Hologic and GE Healthcare, can now enter the market through the 510(k) versus PMA route, according to a final rule and special controls guidance issued Nov. 4.

FDA Reclassifications In Brief

Digital mammography: FDA 1proposes May 30 to downclassify full field digital mammography systems from Class III to Class II, following the 2006 recommendation of its Radiological Devices Panel (2"The Gray Sheet" May 29, 2006, p. 6). The agency also released a special controls 3draft guidance outlining proposed electrical safety and physical laboratory 510(k) testing requirements. Comments on the proposed reclassification and draft guidance are due Aug. 29

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel